Key result
Systemic nab-paclitaxel after coronary stenting proves safe at doses below 70 mg/m2 with no early MACE.
Why the study?
Does systemic nab-paclitaxel safely prevent in-stent restenosis and major adverse cardiac events in patients undergoing stenting of a single de novo lesion?
Does systemic nab-paclitaxel safely prevent in-stent restenosis and major adverse cardiac events in patients undergoing stenting of a single de novo lesion?
Systemic nab-paclitaxel is safe and well tolerated at intravenous doses below 70 mg/m2 following coronary stenting.
Authors
No takes yet. Share an insight, caveat, or question.
Supports low-dose nab-paclitaxel tolerability post-stenting in small cohort; leaves open efficacy for restenosis prevention in randomized trials.
Margolis et al. (2007) studied In-stent restenosis (n=23). Systemic nab-paclitaxel was evaluated on Safety and major adverse cardiac events (MACE) at 2 and 6 months. Systemic nab-paclitaxel was well tolerated at doses below 70 mg/m2 after coronary stenting, with no MACE at 2 months and 4 target lesion revascularizations at 6 months among 23 patients.
Synapse has enriched 4 closely related papers on similar clinical questions. Consider them for comparative context: